Releases Details
Grant of Options and PDMR Dealing
("
Grant of Options and PDMR Dealing
Option Grants to PDMRs |
|
|
400,000 |
|
40,000 |
|
40,000 |
Total |
480,000 |
Options granted to
Of the option granted to
The Option Grants have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of
About
MaxCyte Contacts:
US IR Adviser |
+1 415-937-5400
|
Nominated Adviser and Joint Corporate Broker Panmure Gordon Corporate Broking |
+44 (0)20 7886 2500 |
|
+44 (0)203 709 5700
|
About
At
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
|
a) b) c) |
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
a) President and CEO b) Non-Executive Director c) Non-Executive Director |
|||
b)
|
Initial notification /Amendment
|
Initial notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
|
|
|||
b)
|
LEI
|
54930053YHXULRFCU991 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Common Stock of |
|||
|
|
||||
Identification code |
US57777K1060 |
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options of common stock |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Exercise Price(s) |
Volume(s) |
|
|
|
|
a) |
400,000 |
|
|
|
|
b) |
40,000 |
|
|
|
|
c) |
40,000 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
480,000 |
||||
|
|
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
|
|||
f)
|
Place of the transaction
|
USStock Exchange, Nasdaq |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the